Business Context and Reporting Period
This Form 8-K, filed on March 8, 2019, by Bristol-Myers Squibb Company (BMS), provides financial information related to its proposed acquisition of Celgene Corporation. The filing references a Merger Agreement entered into on January 3, 2019, under which a BMS subsidiary will merge with Celgene. The financial data presented covers Celgene's historical performance for the three-year period ended December 31, 2018, and unaudited pro forma combined financial information for the year ended December 31, 2018.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it incorporates by reference the following documents containing the actual data:
- Exhibit 99.1: Audited consolidated financial statements of Celgene Corporation for the years ended December 31, 2018, 2017, and 2016.
- Exhibit 99.2: Unaudited pro forma condensed combined financial information of BMS and Celgene, including a balance sheet as of December 31, 2018, and a statement of earnings for the year ended December 31, 2018.
The pro forma information is presented for informational purposes only and does not represent actual results of operations had the companies been combined during the periods presented.
Material Changes and Transaction Status
The primary material event is the progression of the acquisition of Celgene. Key developments include:
- Merger Agreement: Executed on January 3, 2019.
- Regulatory Filings: A registration statement on Form S-4 was filed on February 1, 2019, and declared effective by the SEC on February 22, 2019.
- Shareholder Communication: Definitive joint proxy statements/prospectuses were mailed to stockholders on or about February 22, 2019.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the anticipated benefits of the transaction, including synergies, cash flow generation, and accretion to cash earnings per share. Management explicitly disclaims any obligation to update these projections. Significant risks and uncertainties identified include:
- Transaction Risks: Failure to satisfy closing conditions, delays in or denial of regulatory approvals, and inability to achieve anticipated synergies.
- Operational Risks: Difficulties in integrating Celgene's business, diversion of management attention, and potential disruption to business relationships.
- Financial Risks: Potential decline in credit ratings, increased indebtedness, and variability in cash flow generation.
- Market and Legal Risks: Changes in government regulations (Medicare, Medicaid, 340B), pricing pressures, patent expirations, litigation outcomes, and product safety concerns.
Investor Verification Checklist
- Review the definitive joint proxy statement/prospectus (Form S-4) for detailed terms of the merger and voting instructions.
- Examine Exhibit 99.1 for Celgene's audited historical financial performance and debt levels.
- Analyze Exhibit 99.2 for the unaudited pro forma combined financial position and earnings impact of the acquisition.
- Verify the status of regulatory approvals required to consummate the transaction.
- Assess the specific assumptions used by management regarding synergies and future cash flows in the forward-looking statements.